Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT02596035

Public ClinicalTrials.gov record NCT02596035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated adverse events (IMAEs), in patients treated with Nivolumab.

Study identification

NCT ID
NCT02596035
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
197 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 7, 2016
Primary completion
Mar 18, 2018
Completion
May 23, 2021
Last update posted
Oct 26, 2022

2016 – 2021

United States locations

U.S. sites
39
U.S. states
19
U.S. cities
38
Facility City State ZIP Site status
Local Institution - 0030 Phoenix Arizona 85016
Comprehensive Blood And Cancer Center Bakersfield California 93309
St. Jude Hospital Yorba Linda Fullerton California 92835
Cancer Care Associates Medical Group, Inc. Redondo Beach California 90277
Sansum Santa Barbara Medical Foundation Clinic Santa Barbara California 93105
University Of Colorado Aurora Colorado 80045
Local Institution - 0028 Grand Junction Colorado 81501
Local Institution - 0018 Lakewood Colorado 80228
Local Institution - 0008 Fort Myers Florida 33901
Baptist Health Medical Group Oncology Miami Florida 33176
Local Institution - 0007 St. Petersburg Florida 33705
Local Institution - 0054 Tampa Florida 33612-9497
Illinois Cancer Specialists Niles Illinois 60714
Local Institution - 0052 Fort Wayne Indiana 46845
Norton Cancer Institute Louisville Kentucky 40202
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Baltimore Maryland 21231
HCA Midwest Division Kansas City Missouri 64132
Southeast Nebraska Hematology & Oncology Consultants, P.C. Lincoln Nebraska 68510
Local Institution - 0011 Omaha Nebraska 68130
Urology Cancer Center Laboratory Omaha Nebraska 68130
Local Institution - 0014 Las Vegas Nevada 89169
Local Institution - 0053 Buffalo New York 14263
Broome Oncology Johnson City New York 13790
Local Institution - 0055 New York New York 10065
Local Institution - 0001 Tulsa Oklahoma 74146
Local Institution - 0016 Portland Oregon 97213-2982
Local Institution - 0020 Charleston South Carolina 29414
Local Institution - 0005 Chattanooga Tennessee 37404
Local Institution - 0012 Germantown Tennessee 38138
Local Institution - 0004 Nashville Tennessee 37203
Local Institution - 0015 Dallas Texas 75246
The Center For Cancer And Blood Disorders Fort Worth Texas 76104
Local Institution - 0034 Houston Texas 77024
Local Institution - 0021 San Antonio Texas 78217
Texas Cancer Center - Sherman Sherman Texas 75090-0504
Local Institution - 0032 Norfolk Virginia 23502
Local Institution - 0047 Richmond Virginia 23230
Local Institution - 0017 Roanoke Virginia 24014
Local Institution - 0039 Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02596035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 26, 2022 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02596035 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →